Aventis Pharma S.a.

Rhone-poulenc Rorer S.a.

Medarex Inc.

Other

University of California

Aventis Pharmaceuticals Products Inc.

Centelion

Medisup International, N.v.

Laboratoire European De Biotechnologie S.a.

Patrick Benoit

Patrice Denefle

Michael Gerard Tovey

Ivan Plavec

Francois Meyer

Michel Perricaudet

Emmanuelle Vigne

Nicolas Duverger

Deborah Maguire

Debborah Maguire

Kenneth R Chien

Michael R Hayden

Laurent Pradier

Ju Chen

Gerd Assmann

Harald Funke

Jean-Michel Itier

Gunter Tremp

G&eacute;rard Turpin

Sandrine Seguret

Louis Marie Houdebine

G&eacute;rald Luc

Jean-Charles Fruchart

Eric Bruckert

M E Suzanne Lewis

Didier Branellec

Bertrand Schwartz

Véronique Blanchard-Bregeon

Caty Casas Louzao

The present invention relates to nonhuman transgenic animals exhibiting major disorders related to Alzheimer's disease. The animals can be used for demonstrating compounds intended for the treatment of Alzheimer's disease.

Transgenic animals exhibiting major disorders related to Alzheimer's disease

The invention relates to a monoclonal antibody directed against the human interferon class I receptor (IFN-R) characterized by the following properties: it recognizes the extracellular domain of the human IFN-R, and it has a neutralizing capacity against the biological properties of the human type I-IFN. It further concerns their use for the diagnosis.

Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon

The invention relates to novel promoter sequences derived from a portion upstream of the coding sequence of the gene for the CARP protein (Cardiac Ankyrin Repeat Protein), and which are capable of controlling the level and the specificity of expression of a transgene in vivo in cardiac muscle cells. The invention thus describes novel compositions, constructs, vectors and their uses in vivo for the transfer and expression of a nucleic acid in vivo in cardiac muscle cells. The subject of the present invention is also the use of the promoter sequences for generating transgenic animals which constitute models for studying certain cardiac pathologies.

Sequences upstream of the CARP gene, vectors containing them and uses thereof

Monoclonal antibodies against the interferon receptor, with neutralizing activity against type 1 interferon

Recombinant viruses comprising a heterologous DNA sequence coding for a lipase involved in lipoprotein metabolism. The invention also concerns the preparation and use in therapy of said recombinant viruses, especially for the treatment or prevention of dyslipoproteinemia-related pathologies.

Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same

A monoclonal antibody is provided which is directed against the human interferon type I receptor (IFN-R), which recognizes the extracellular domain of the human IFN-R and which has neutralizing capacity against the biological properties of human type I-IFN. Diagnostic and therapeutic applications for the monoclonal antibody also are provided.

Isolated peptide or polypeptide of the extracellular portion of the human interferon receptor (IFN-R).

The present invention concerns defective recombinant adenoviruses containing an inserted gene encoding apolipoproteins, pharmaceutical compositions comprising the adenovirus, and their use for the treatment or prevention of pathologies linked to dyslipoproteinemias.

Recombinant adeno viruses comprising an inserted gene encoding apolipoprotein and their use in gene therapy for dyslipoproteinemias

The present invention relates to variants of the human apolipoproteine A-I comprising a cystein in position 151, the corresponding nucleic acids and the vectors containing them. It also relates to pharmaceutical compositions comprising said elements and their utilization, particularly in genic therapy.

Variants of apolipoprotein A-I

Monoclonal antibodies against the interferon receptor, with neutralizing

Recombinant adero viruses comprising an inserted gene encoding

Dyslipoproteinaemia-sensitized transgenic rabbit

Growing community of inventors

Paris, France

Patrick Benoit